MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Testoluten Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Testoluten (Testes Cytomax A-13) is a natural testicular peptide complex from Vladimir Khavinson's bioregulator program, sold as a 10 mg oral capsule. It is a cytomedin, the natural counterpart of the synthesized testes tetrapeptide Testagen (Lys-Glu-Asp-Gly, KEDG). Rather than acting on a surface receptor, its short peptides are hypothesized to enter the cell nucleus and bind specific DNA promoter sequences, nudging Leydig-cell steroidogenesis and Sertoli-cell support of spermatogenesis (PMID 34834147, 22117547). Mechanistic support is in-vitro and from cytomedin organotypic-culture work (PMID 11213728); testes-specific human evidence is limited to small Russian reports, and there are no Western trials, so Testoluten is an unapproved supplement/research compound. Real-world dosing is oral: 1-2 capsules once or twice daily (about 10-20 mg/day) before food for a one-month seasonal course. The educational subcutaneous reference uses a 20 mg vial reconstituted with 2 mL bacteriostatic water (10 mg/mL) so a 1-2 mg dose is 10-20 units on a U-100 syringe. This is reference information, not medical advice.
Reconstitute: Add 2 mL bacteriostatic water → 10 mg/mL concentration.
Typical dose: 10 mg/capsule; ~10-20 mg/day oral, 10-30 day course
Easy measuring: At 10 mg/mL, 1 unit = 0.01 mL = 0.1 mg (100 mcg) on a U-100 insulin syringe.
Storage: Real-world capsules: store dry and dark at +2 to +25 °C. For the educational reconstitution model: keep a lyophilized vial at -20 °C long term or 2-8 °C short term, protected from light; once reconstituted, keep refrigerated at 2-8 °C and use within about 3-4 weeks.
Half-life: Not formally characterized; the constituent short peptides are expected to have a plasma half-life of minutes (rapid peptidase hydrolysis), with effects attributed to downstream gene-expression changes that outlast the peptide.
Route: Real-world route is oral (10 mg capsules, 1-2 caps once or twice daily before food); this page additionally models a once-daily subcutaneous reconstitution reference, a route not validated for Testoluten.
Status: Not FDA or EMA approved; no published Western trials; a Khavinson Cytomax bioregulator sold as a dietary supplement / research compound only.
About Testoluten
Testoluten (Testes Cytomax A-13) is a testes-targeted Khavinson peptide bioregulator: a natural low-molecular-weight peptide complex extracted from animal testicular tissue and marketed as a 10 mg oral capsule [1][5]. In the Russian gerontology framework these "Cytomax" complexes are taken by mouth as short seasonal courses; clinically and as sold, this is an oral supplement, not an injection, so the subcutaneous figures below are an educational reconstitution reference only and are scaled to be measurable on a U-100 syringe [2][3]. There are no published Western trials of Testoluten, so every dose here is illustrative rather than a validated clinical regimen.
Educational guide for reconstitution and short-course dosing.
Frequency: Real-world use is oral, 1-2 capsules once or twice daily (about 10-20 mg/day) taken 30 minutes before food for a roughly one-month course, repeated two to three times per year in the bioregulator literature [1]. For the educational subcutaneous model, reconstituting a 20 mg vial with 2 mL of bacteriostatic water yields 10 mg/mL, so a 1-2 mg daily reference dose corresponds to 10-20 units on a U-100 insulin syringe.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 2 mL of bacteriostatic water into a sterile syringe (this is the educational injectable model; the real product is an oral 10 mg capsule that needs no reconstitution).
Inject the water slowly down the inner wall of the 20 mg vial; do not spray it directly onto the lyophilized powder.
Gently swirl or roll the vial until the powder fully dissolves into a clear solution; never shake, which can shear the peptide and cause foaming.
The result is 10 mg/mL, so 1 mg is 10 units (0.10 mL) and 2 mg is 20 units (0.20 mL) on a U-100 insulin syringe; swab the stopper and draw the daily reference dose.
Inject subcutaneously once daily during the course, store the vial refrigerated at 2-8 °C between uses, and discard after the stability window (about 3-4 weeks).
Interactive Testoluten Syringe Calculator
Currently visualizing the 20 mg vial reconstituted with 2 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 20mg dry powder in 2mL water yields 10.00 mg/mL. To evaluate a 250mcg dose, pull to 2.5 units (3 syringe ticks).
U-100 Syringe Representation
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Phase | Dose per injection | Units (per injection) |
|---|---|---|
| Introductory educational SC reference (days 1-3) | 500 mcg | 5 units (0.05 mL) |
| Conservative course (days 1-10) | 1000 mcg (1 mg) | 10 units (0.10 mL) |
| Standard course (days 4-30) | 2000 mcg (2 mg) | 20 units (0.20 mL) |
Administration guidelines: Refer to guidelines | 2 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 20 mg vial.
Peptide Vials (Testoluten, 20 mg each):
- checkReal product note: sold as oral 10 mg capsules (20- and 60-capsule boxes); the 20 mg vial below is the educational injectable model only.
- checkOne 10-day educational course at the standard 2 mg/day uses a full 20 mg vial (a 1 mg/day course uses about half a vial).
- check8-week window (about 2 short courses): 2 vials.
- check12-week window (about 3 short courses): 3 vials; 16-week window (about 4 short courses): 4 vials.
Insulin Syringes (U-100):
- checkOne 0.3 mL (30-unit) syringe per daily injection in the educational model, about 10 per 10-day course.
- check8-week window: roughly 20 syringes.
- check12-week window: roughly 30 syringes.
- check16-week window: roughly 40 syringes.
Bacteriostatic Water (30 mL bottles): Use 2 mL per vial for reconstitution.
- checkEach reconstituted 20 mg vial consumes 2 mL of bacteriostatic water.
- checkEven 4 vials across a 16-week schedule use only about 8 mL, so a single 30 mL bottle covers every course.
- checkDiscard any vial not used within its stability window rather than over-diluting to extend it.
Alcohol Swabs: clean the vial stopper and injection site before each use.
- checkUse 2 swabs per injection (vial top plus skin), about 20 per 10-day course.
- check8-week window: about 40 swabs; 12-week window: about 60 swabs; 16-week window: about 80 swabs.
- checkA single 100-count box comfortably covers a full year of seasonal courses.
Mechanism of Action (MOA)
Testoluten is a natural peptide complex (the testes "Cytomax," designated A-13) isolated from the testicular tissue of young animals within Vladimir Khavinson's bioregulator program at the St. Petersburg Institute of Bioregulation and Gerontology [1][5]. It belongs to the cytomedin/Cytomax family of low-molecular-weight peptide preparations, the natural counterparts of the synthesized "Cytogen" short peptides; the corresponding synthesized testes analog is the tetrapeptide Testagen (Lys-Glu-Asp-Gly, KEDG) [2]. Unlike peptide hormones, these complexes are not thought to act through a classical cell-surface receptor. The prevailing Khavinson hypothesis is that the short, charged peptides they contain are small enough to enter the cytoplasm and nucleus, where they bind specific nucleotide sequences in gene-promoter regions, locally modulate the DNA double helix, and tune transcription of a tissue-appropriate set of genes [2][4][7]. In this framework a testes-targeted complex is proposed to "switch on" the resident gene programs of Leydig cells (steroidogenesis) and Sertoli cells (support of spermatogenesis) rather than supplying testosterone or a gonadotropin-like signal [1]. Mechanistic plausibility for the broader class comes from experiments showing fluorescence-labeled Khavinson peptides penetrating the nucleus and nucleolus of cultured cells and binding defined DNA oligonucleotides in vitro [4], from spatial docking models of peptide-DNA complexes [7], and from the observation that such peptides can act as epigenetic modulators of DNA methylation [6]. Classic cytomedin work also showed that organ-specific natural peptide complexes stimulate development of the matching tissue in organotypic culture, the experimental paradigm under which preparations like Testoluten were originally characterized [5]. It must be stressed that the testes-specific evidence is thin: there are no Western randomized trials, and the human data are confined to small Russian reports. Pharmacokinetics have not been formally characterized for Testoluten. The intact constituent peptides are expected to be hydrolyzed rapidly by gastrointestinal and plasma peptidases, giving a free-peptide plasma half-life on the order of minutes; any durable effect is attributed to downstream gene-expression changes that outlast the peptide rather than to sustained drug levels [3]. The real-world product is an oral capsule (10 mg of peptide complex), and the low-dose oral route is used precisely because these peptides are quickly degraded and only a small fraction of intact peptide is thought to reach target cells. Clinically and as sold, Testoluten is taken by mouth: 1-2 capsules once or twice daily (about 10-20 mg/day) 30 minutes before food, for a roughly one-month course repeated seasonally. The once-daily subcutaneous reconstitution described on this page is an educational modeling convention only — no injectable Testoluten exists — and the 1-2 mg/day figures are scaled to be measurable on a U-100 syringe, analogous to how related Khavinson injectable peptides are dosed [8][9]. Testoluten remains an unapproved supplement/research compound, and all dosing here should be read as reference information, not therapeutic guidance.
Clinical Trial Efficacy Highlights
- starTestoluten is a member of the Khavinson Cytomax (cytomedin) family; the foundational "Peptides and Ageing" framework lays out the tissue-specific geroprotector model under which testes-targeted complexes were designed, but it presents them as preclinical organ analogues rather than clinically validated therapies [1].
- starA 2021 systematic review in Molecules summarizing the Khavinson short-peptide program describes how 2-7 residue peptides regulate tissue-specific gene expression and protein synthesis and catalogs the synthesized organ analogs (including the testes peptide), providing the mechanistic rationale for Testoluten while reporting no human efficacy data for it [2].
- starChalisova, Khavinson and colleagues showed that natural organ-specific cytomedins stimulate development of the matching tissue in organotypic culture at nanogram concentrations, the classic experimental paradigm under which preparations like the testes Cytomax were characterized; this is preclinical, tissue-culture evidence, not clinical proof [5].
- starFedoreyeva and colleagues (2011) demonstrated with fluorescence-labeled Khavinson peptides that such short peptides penetrate the cytoplasm, nucleus, and nucleolus of cells and bind specific DNA oligonucleotide sequences in vitro, lending experimental plausibility to the nuclear DNA-binding mechanism invoked for testes bioregulators [4].
- starKhavinson, Lin'kova and Tarnovskaya (2016) constructed spatial docking models of peptide-DNA complexes for short Khavinson peptides, supporting the gene-regulation model proposed for the family but not testing Testoluten or testicular endpoints directly [7].
- starA 2019 review in Clinical Epigenetics independently catalogued Khavinson di- to tetrapeptides as endogenous epigenetic modulators that can influence DNA methylation, situating the Testoluten/Testagen concept within a broader, externally authored peptide-epigenetics literature [6].
- starAt the class level, controlled clinical work on other Khavinson bioregulators provides the strongest human signal: a 6-8 year study found pineal and thymic peptides normalized physiological function in elderly people [8], and a 15-year randomized follow-up of a pituitary peptide reported reduced mortality and slowed aging [9]; both studied different peptides and cannot be extrapolated to Testoluten.
- starTestes-specific human data are limited to small, unreplicated Russian reports describing changes in androgen status, which lack randomization, blinding, and independent confirmation; no peer-reviewed Western trial has evaluated Testoluten for testosterone, fertility, or any clinical endpoint.
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningNo controlled human safety data exist for Testoluten; its adverse-effect profile is essentially uncharacterized, and the points below are extrapolated from the Khavinson bioregulator class and general peptide use.
- warningAs an oral animal-derived peptide complex, it carries a theoretical risk of allergy or hypersensitivity; the manufacturer lists individual intolerance of the components as a contraindication.
- warningFor the educational subcutaneous model, injection can cause local reactions including redness, itching, swelling, bruising, or transient pain, plus a theoretical risk of immune or hypersensitivity reactions; stop and seek care for rash, hives, facial or throat swelling, or difficulty breathing.
- warningBecause it is animal tissue-derived and not manufactured to pharmaceutical standards, contamination, endotoxin, inconsistent peptide content, and (for any injectable preparation) sterility cannot be assumed.
- warningIt is explicitly contraindicated in pregnancy and lactation by the supplier and has not been studied in children; it should be avoided in these groups.
- warningThere are no drug-interaction studies; men taking testosterone, gonadotropins, 5-alpha-reductase inhibitors, or other endocrine or prostate medications should not assume Testoluten is inert or compatible, and anyone with prostate disease or hormone-sensitive cancer should consult a clinician first.
- warningBecause the proposed mechanism involves modulating gene expression in proliferative reproductive tissue, long-term, fertility, and oncologic safety are entirely unknown.
- warningRegulatory status: Testoluten is not approved by the FDA, EMA, or any major regulator as a drug; it is sold as a dietary supplement / research compound, the manufacturer's claims are not evaluated by the FDA, and it is not intended to diagnose, treat, cure, or prevent any disease.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical Testoluten dosage?expand_more
As sold, Testoluten is an oral supplement: the typical Testoluten dosage is 1-2 capsules (each 10 mg) taken once or twice daily, about 10-20 mg per day, 30 minutes before food, for a roughly one-month course that is often repeated two to three times per year. There is no clinically validated dose, because no controlled human trials have established a safe or effective amount. The subcutaneous figures on this page (about 1-2 mg/day from a 20 mg reconstituted vial) are an educational reconstitution reference only, since no injectable Testoluten product exists. Treat all of these as illustrative reference values, not medical advice.
Is Testoluten FDA approved?expand_more
No. Testoluten is not approved by the FDA, the EMA, or any other major regulator as a drug, and there are no published Western clinical trials. It originates from the Khavinson bioregulator program in Russia and is sold as a dietary supplement (a natural testes peptide complex) or for research use. The manufacturer's statements are explicitly not evaluated by the FDA, and the product is not intended to diagnose, treat, cure, or prevent any disease. Nothing here should be read as a claim that it is safe or effective.
How do you reconstitute Testoluten for the educational subcutaneous model?expand_more
The real product is an oral capsule that needs no reconstitution. For the educational injectable reference, draw 2 mL of bacteriostatic water and inject it slowly down the inner wall of a 20 mg vial, then swirl gently (never shake) until the powder dissolves into a clear solution. This gives 10 mg/mL, so 1 mg is 10 units (0.10 mL) and 2 mg is 20 units (0.20 mL) on a U-100 insulin syringe. Swab the stopper before each draw, keep the vial refrigerated at 2-8 °C, and discard after about 3-4 weeks. This Testoluten reconstitution math is a modeling convention, not a validated route.
What is Testoluten's half-life?expand_more
Testoluten's half-life has not been formally characterized in published pharmacokinetic studies. As a natural complex of short peptides, the intact molecules are expected to be broken down rapidly by gastrointestinal and plasma peptidases, giving a free-peptide plasma half-life on the order of minutes. The Khavinson framework attributes any longer-lasting effect to downstream changes in gene expression that outlast the peptide itself, rather than to sustained circulating drug levels, which is part of why these bioregulators are dosed in short seasonal courses rather than continuously.
Can Testoluten be stacked with other Khavinson bioregulators?expand_more
In the bioregulator literature, tissue-specific Cytomax and Cytogen peptides are often described as being combined (for example a testes peptide alongside pineal, thymic, vascular, or prostate peptides such as Endoluten, Vladonix, or Prostamax), and Testoluten is frequently marketed alongside them. However, there are no controlled data on the safety, interactions, or added benefit of any such stack, and combining unapproved supplements multiplies the unknown risks. This is general information, not medical advice; anyone considering these compounds should consult a qualified clinician, especially if they have prostate disease or take hormonal medications.
Related Guides & Tools
Step-by-step references for reconstituting, measuring, and storing Testoluten, plus the universal dosing calculator.
Academic References & Study Citations
Khavinson VKh. Peptides and Ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11-144. View Scientific Paper →
Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. View Scientific Paper →
Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149. View Scientific Paper →
Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Mosc). 2011;76(11):1210-1219. View Scientific Paper →
Chalisova NI, Khavinson VKh, Davydenko VV, Dorovskikh AA, Verbovaia TA, Penniyaynen VA. [Effect of cytomedins on development of organotypic culture of various tissues from the internal organs of rats]. Tsitologiia. 2000;42(12):1144-1147. View Scientific Paper →
Janssens Y, Wynendaele E, Vanden Berghe W, De Spiegeleer B. Peptides as epigenetic modulators: therapeutic implications. Clin Epigenetics. 2019;11(1):101. View Scientific Paper →
Khavinson VKh, Lin'kova NS, Tarnovskaya SI. Short Peptides Regulate Gene Expression. Bull Exp Biol Med. 2016;162(2):288-292. View Scientific Paper →
Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003;24(3-4):233-240. View Scientific Paper →
Korkushko OV, Khavinson VKh, Shatilo VB, Antonyk-Sheglova IA. Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up. Bull Exp Biol Med. 2011;151(3):366-369. View Scientific Paper →